Liquid biopsy, Real World Data & Artificial Intelligence. A new clinical trial model?
Oncology has always focused on treating tumours according to their characteristics, regardless of their location. This personalised treatment of patients is possible thanks to the knowledge of molecular alterations “targets”, which allow targeted treatment with specific drugs.
Unfortunately, despite the progress that has been made in this area, only a few patients have been identified as having “known targets” that would allow them to benefit from this strategy.
Hopefully, precision oncology has new tools, such as liquid biopsy tests, that can help identify which patients may benefit from targeted therapy.
In addition, the digitisation of medical data provides valuable information that we must learn to use.
The development of these therapies has progressed rapidly, but the clinical trial model has not kept pace and does not integrate these new tools.
In this roundtable, we will review the benefits of liquid biopsy (BL), analyse real-world data (RWD) through large databases (BigData), and discover the contribution of artificial intelligence (AI). All this with the aim of proposing a new trial model based on BL that will allow us to rescue those patients for whom no “targets” are found at the outset.
